| Document |
Document Title |
|
WO/2023/250272A2 |
Disclosed are compositions and methods for targeted treatment of SSTR-expressing cancers. For example, disclosed herein are Bispecific T-Cell Engaging (BiTE) molecules (fusion polypeptides) (also referred to herein as bispecific molecule...
|
|
WO/2023/249071A1 |
[Problem] To provide a novel T-cell receptor (TCR) which specifically recognizes glypican 3 (GPC3). [Solution] Provided is a T-cell receptor (TCR) that includes one amino acid sequence selected from the group consisting of the amino acid...
|
|
WO/2023/250022A1 |
The present disclosure provides CCR5 binding agents that are useful in preventing or treating CCR5 and CCR2 dysregulation and resulting conditions and symptoms thereof, including NASH and NAFLD. The present disclosure provides a method o...
|
|
WO/2023/247717A1 |
The present invention relates to G protein peptidomimetics, in particular Gq/11 protein peptidomimetics, capable of stabilizing a GPCR, in particular a Gq/11 protein-coupled receptor, in an active conformational state. The G protein pept...
|
|
WO/2023/250512A1 |
The present disclosure relates to compositions and methods comprising epigenetic editors for epigenetic modification of CIITA, as well as nucleic acids and vectors encoding the same. Also disclosed are cells epigenetically modified by th...
|
|
WO/2023/250493A1 |
Compositions, methods and therapeutic regimens of mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugates for the treatment of severe hypertriglyceridemia are provided.
|
|
WO/2023/249425A1 |
The present invention relates to a fusion protein, in which an anti-CD73 antibody or an antigen-binding fragment thereof, and IL-2 are bound, and to use thereof. The fusion protein, comprising: an anti-CD73 antibody or an antigen-binding...
|
|
WO/2023/246621A1 |
A coxsackievirus A10 strain and a use thereof. Amino acid sequences of VP4, VP3, VP2 and VP1 proteins of the coxsackievirus A10 strain are respectively as represented by SEQ ID NOs 1, 2, 3 and 4, and amino acid sequences of 2A, 2B, 2C, 3...
|
|
WO/2023/249439A1 |
The present invention relates to a novel peptide capable of inhibiting TGF-β signaling, and use thereof. The peptide of the present invention can inhibit a TGF-β-induced signaling pathway or inhibit the expression of TGF-β, and thus c...
|
|
WO/2023/247781A1 |
The present invention relates to short peptides or salts thereof which can be modified with appropriate hydrophobic tails to generate amphiphilic molecules useful for the intracellular delivery of molecules of biological interest. Thus, ...
|
|
WO/2023/250481A2 |
Disclosed herein is use of a Rickettsia OmpB β-peptide epitope that binds host immune IgM as a specific diagnostic substrate for detecting patient immune IgM antibody to both spotted fever group and typhus group Rickettsia.
|
|
WO/2023/246071A1 |
The present invention provides an mreC mutant and use thereof in L-valine fermentative production. The mreC mutant is a protein obtained by mutating proline at position 150 in the wild-type mreC amino acid sequence into leucine. The intr...
|
|
WO/2023/249422A1 |
The present application discovers a histidine export protein having an ability to export L-histidine or a variant thereof, and expresses same in a microorganism having an ability to produce L-histidine, thereby dramatically improving L-h...
|
|
WO/2023/249078A1 |
The purpose of the present invention is to provide a senescence inhibitor that utilizes a material of biological origin. The present invention is directed to a senescence inhibitor containing a vitamin D binding protein.
|
|
WO/2023/249408A1 |
The present invention relates to a recombinant PH20 polypeptide in which 1 to 7 amino acid residues have been deleted from the N-terminus of mature animal wild-type PH20, and a use thereof. The PH20 polypeptide, in which enzyme activity ...
|
|
WO/2023/247640A1 |
Provided herein is an insulin-Fc fusion polypeptide comprising a single-chain insulin and an Fc region polypeptide. Further provided is a conjugate of two insulin-Fc fusion polypeptides, wherein the two insulin-Fc fusion polypeptides are...
|
|
WO/2023/250459A2 |
The disclosure relates to the engineering of IL-35 cytokine polypeptides to achieve improved therapies for inflammatory diseases and conditions. Accordingly, aspects of the disclosure relate to a polypeptide comprising SEQ ID NO:2, where...
|
|
WO/2023/250490A1 |
This invention relates to compositions and methods comprising epigenetic editors for epigenetic modification of TRAC, as well as nucleic acids and vectors encoding the same. Also disclosed are cells epigenetically modified by the epigene...
|
|
WO/2023/246639A1 |
A coxsackievirus A6 type strain, and an immunogenic composition and use thereof. The amino acid sequences of VP4, VP2, VP3 and VP1 proteins of the coxsackievirus A6 type strain are respectively shown in SEQ ID NO. 1, 2, 3 and 4. The amin...
|
|
WO/2023/201350A9 |
A composition and method for treatment of opioid use disorder (OUD) is provided by expressing a novel mu receptor mutant, LAMuOR (Low Affinity Mu Opioid Receptor), with reduced binding affinity for opioids such that it is activated only ...
|
|
WO/2023/250127A1 |
This document provides methods and materials for binding a chimeric antigen receptor (CAR) to a TRAILshort polypeptide. For example, a CAR that binds to a TRAILshort polypeptide and methods and materials for using cells expressing such a...
|
|
WO/2023/248009A1 |
Human interleukin-2 (IL-2) cytokine fusions are provided. In particular, provided are IL-2 cytokines and IL-2 cytokine fusions that have an increased binding capacity for IL-2Rβ receptor as compared to wild-type IL-2 for use in dosing a...
|
|
WO/2023/250478A1 |
The present disclosure provides recombinant bacterial cells that have been engineered with genetic circuitry which allow the recombinant bacterial cells to sense a patient' s internal environment and respond by turning an engineered meta...
|
|
WO/2023/250469A1 |
Compositions, foodstuff and methods are provide herein from cereal plant or a part thereof, wherein the plant or part thereof has an altered (I,3;l,4)-p-glucan content as compared to a wild-type cereal plant or part thereof, wherein said...
|
|
WO/2023/250055A1 |
The disclosure provides live attenuated measles vectors encoding in their genome one or more heterologous genes for herpes simplex virus (HSV) proteins, e.g., glycoprotein B, glycoprotein C, glycoprotein D, and variants thereof, as well ...
|
|
WO/2023/250484A2 |
This disclosure relates to therapeutics containing recombinant IL-37, chimeric antigen receptors, nucleic acids, or vectors encoding the same. In certain embodiments, this disclosure relates to methods of treating cancer comprising admin...
|
|
WO/2023/247936A1 |
A bacterium of the class Clostridia comprising a heterologous nucleic acid molecule; wherein the heterologous nucleic acid molecule comprises at least one antigen gene comprising a region encoding at least one antigen and a promoter oper...
|
|
WO/2023/245971A1 |
Disclosed is a method for improving adhesion force of a recombinant mussel foot protein. According to the method, by means of bioinformatics and molecular dynamics simulation, solvent accessibility of protein molecule amino acid residues...
|
|
WO/2023/250168A2 |
Provided herein are recombinant T-cell receptors (TCRs) that can selectively recognize the MAGE-A4-derived peptide GVYDGEEHSV or KVEEHVVRV when presented by HLA-A*0201 sufficiently to activate the recombinant T cell. TCRs provided herein...
|
|
WO/2023/246928A1 |
The present invention relates to an improved GLP-1 receptor agonist, a fusion protein containing the improved GLP-1 receptor agonist, a polynucleotide encoding the fusion protein, a vector containing the polynucleotide, a cell, and the u...
|
|
WO/2023/249463A1 |
The present invention relates to an immune cell expressing an immune checkpoint regulator so as to overcome an immune checkpoint, a preparation method therefor, and a pharmaceutical composition comprising the immune cell, and, more speci...
|
|
WO/2023/246938A1 |
Therapeutic mRNA for solid tumors and a use thereof. The mRNA comprises mRNA encoding at least two of the following cytokines: IFNα, IL-7, TNFα, IL-12A, IL-12B, GM-CSF, and IL-12sc. The mRNA has a prevention and treatment effect on tum...
|
|
WO/2023/250148A1 |
Disclosed herein are compositions and methods comprising epigenetic editing systems for epigenetic editing or cells, nucleic acids, and vectors comprising the same. Also disclosed are epigenetically modified chromosomes.
|
|
WO/2023/250523A2 |
A method for treating neurotrophic keratitis (NK) includes administering to a subject in need thereof a composition that includes a peptide having the amino-acid sequence selected from SEQ ID NO: 1-7. The pharmaceutical composition conta...
|
|
WO/2023/250440A1 |
Extracellular vesicles comprising a bi-layer lipid membrane comprising an inner layer and an outer layer and a first recombinant protein comprising a first transmembrane moiety embedded between the inner layer and the outer layer of the ...
|
|
WO/2023/250382A1 |
Microorganisms are genetically engineered to continuously co-produce amino acids, proteins, microbial biomass, chemicals, or any combination thereof by microbial fermentation, particularly by microbial fermentation of a gaseous substrate...
|
|
WO/2023/248008A2 |
Provided herein are degrons, compositions, and chimeric molecules comprising the degrons, and methods of using the degrons and chimeric molecules.
|
|
WO/2023/247770A1 |
The present invention provides a method of treating or preventing a medical condition associated with a herpes virus infection, the method comprising the administration of a therapeutically effective amount of the immune cell comprising ...
|
|
WO/2023/250509A1 |
Disclosed herein are compositions and methods comprising epigenetic editors for epigenetic modification of B2M, as well as nucleic acids and vectors encoding the same. Also disclosed are cells epigenetically modified by the epigenetic ed...
|
|
WO/2023/247889A1 |
The present application relates to compounds and their use in health, in particular in the preventive or curative treatment of inflammatory diseases, microbial or bacterial infections or proliferative or neoplastic pathologies, linked to...
|
|
WO/2023/250389A1 |
Microorganisms are genetically engineered to continuously co-produce amino acids, high-value, specialized proteins, microbial biomass, chemicals, or any combination thereof by microbial fermentation, particularly by microbial fermentatio...
|
|
WO/2023/248105A1 |
Nature-inspired smart materials offer numerous advantages over environment- friendliness and efficiency. Emulating the excellent adhesive properties of mussels foot proteins, where the Lysine is in close proximity with the 3, 4-dihydroxy...
|
|
WO/2023/245543A1 |
The present disclosure provides human fibroblast growth factor 21 (hFGF21) fusion proteins for treating non-alcoholic fatty liver disease (NAFLD), diabetes, diabetic complications, obesity, dyslipidemia, metabolic syndrome, and/or disord...
|
|
WO/2023/250375A1 |
Circular RNA, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In ...
|
|
WO/2023/241391A1 |
The present invention provides a TCR molecule binding to an SSX2 antigen and an application thereof. The TCR molecule can specifically bind to an SSX2 antigen short peptide complex AQIPEIQK-HLA A1101. Meanwhile, effector cells transducin...
|
|
WO/2023/245005A2 |
Aspects of the disclosure relate to compositions and methods for targeted protein degradation. In some embodiments, the disclosure relates to methods of evolving protein degrons to interact with certain small molecule inducers (e.g., VS-...
|
|
WO/2023/242251A1 |
The invention relates to the field of fusion proteins and in particular to fusion proteins comprising a follistatin moiety. The invention also relates to methods of making said fusion proteins, together with pharmaceutical formulations c...
|
|
WO/2023/240458A1 |
Provided in the present invention are a polypeptide inhibitor of foot-and-mouth disease virus and the use thereof. The amino acid sequence of the polypeptide for inhibiting or preventing foot-and-mouth disease virus is as shown in positi...
|
|
WO/2023/244071A1 |
The present invention relates to the therapeutic use of exosome comprising super-repressor-IκB (srIκB) for liver disease. The present invention provides a pharmaceutical composition for preventing or treating liver disease, comprising ...
|
|
WO/2023/242343A1 |
The present application describes T cell receptors specifically binding tumor antigen derived peptides, especially derived from Mitogen-Activated Protein Kinase 8 Interacting Protein 2 (MAPK8IP2), Epstein-Barr Virus (EBV) proteins or Hum...
|
